Lupin announced the completion of the United States Food and Drug Administration (USFDA) inspection carried out at its Tarapur manufacturing (API) facility.
The inspection was carried out between 16 September to 20 September 2019.
The inspection at the Tarapur facility closed with three observations. The Company is confident of addressing them satisfactorily.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)